Rezolute (NASDAQ:RZLT) Sets New 1-Year High - Still a Buy?

Key Points

• Rezolute's stock price reached a new 52-week high of $9.74, closing at $9.49 with a trading volume of 4,009 shares.
• Wall Street analysts maintain a positive outlook on Rezolute, with a consensus rating of "Buy" and an average target price of $14.50.
• Recent quarterly earnings showed Rezolute reported an EPS of ($0.26), below expectations, with forecasts predicting an EPS of ($0.93) for the current fiscal year.

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report)'s stock price reached a new 52-week high on Thursday . The company traded as high as $9.74 and last traded at $9.49, with a volume of 4009 shares changing hands. The stock had previously closed at $9.43.

Wall Street Analysts Forecast Growth

RZLT has been the subject of a number of recent analyst reports. Guggenheim reissued a "buy" rating and set a $15.00 target price on shares of Rezolute in a research report on Monday, September 22nd. Maxim Group lifted their price target on shares of Rezolute from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, September 18th. Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a research report on Thursday, September 18th. BTIG Research restated a "buy" rating and set a $17.00 price objective on shares of Rezolute in a research note on Thursday, September 18th. Finally, HC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Rezolute in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat, Rezolute has an average rating of "Buy" and an average target price of $14.50.

Rezolute Price Performance

The company has a market cap of $841.45 million, a PE ratio of -9.54 and a beta of 0.04. The business has a 50 day moving average of $7.19 and a 200 day moving average of $5.02.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its quarterly earnings data on Wednesday, September 17th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03). Sell-side analysts forecast that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Rezolute

Several institutional investors and hedge funds have recently modified their holdings of RZLT. Rosalind Advisors Inc. bought a new stake in Rezolute in the 2nd quarter worth about $7,766,000. Opaleye Management Inc. boosted its holdings in shares of Rezolute by 94.3% during the 2nd quarter. Opaleye Management Inc. now owns 903,442 shares of the company's stock valued at $4,029,000 after acquiring an additional 438,442 shares during the last quarter. Massar Capital Management LP purchased a new position in shares of Rezolute during the second quarter valued at approximately $126,000. BNP Paribas Financial Markets purchased a new position in shares of Rezolute during the second quarter valued at approximately $25,000. Finally, Boothbay Fund Management LLC lifted its position in Rezolute by 1,745.6% during the second quarter. Boothbay Fund Management LLC now owns 266,671 shares of the company's stock valued at $1,189,000 after purchasing an additional 252,222 shares during the period. 82.97% of the stock is currently owned by institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.